Tag: Regulations

Browse our exclusive articles!

OpenAI’s Sam Altman Disagrees with Elon Musk on Pausing AI Research

OpenAI CEO suggests regulations to keep AI under control while Tesla's co-founder calls for a halt to AI research. Safety standards of OpenAI as a capped profit company are emphasized. Learn why Altman disagrees with Musk's concerns.

OpenAI to Invest in Indian Startups Working on AI, No Pause on AI Progress: Sam Altman

OpenAI CEO Sam Altman believes pausing AI development is not the solution. Instead, he emphasizes the need for regulations to prevent misuse and invests $175M in AI startups in India. He urges Indian officials to discuss AI at the G20 Summit. Read more.

Sam Altman discusses AI regulation with PM Modi

Chatbot creator Sam Altman met with Indian Prime Minister Narendra Modi to discuss AI regulation. He shared that his company, ChatGPT, plans to use net-zero cooling and renewable energy sources to significantly reduce AI's environmental impact. Altman expressed confidence in the development of cleaner energy systems and safer Artificial General Intelligence (AGI). He plans to fund education startups in India and work on education initiatives.

The Future of AI in Finance: Embracing Uncertainty

Nasdaq's CEO suggests using algorithms to combat financial crime using AI technology. Concerns arise regarding the adoption of unexplainable AI, but regulations demand accountability. The potential benefits are present, yet caution is needed before implementing AI technology to financial markets.

Why Open AI CEO Sal Altman Delays GPT-5 Training

OpenAI CEO Sam Altman confirms GPT-5 won't receive training yet due to extensive required work. Expected release in 2024 with improved functionality. Altman emphasizes the importance of lawmakers' involvement in AI regulation.

Popular

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.

Pioneering Research Uncovers Vital Biomarker for Orbital Inflammation

An in-depth study reveals HLF as a potential biomarker for orbital inflammation, offering new insights for diagnosis and treatment strategies.

Subscribe

spot_imgspot_img